Envafolimab is under clinical development by Alphamab Oncology and currently in Phase I for Head And Neck Cancer.

PAX-1 is under clinical development by Komipharm International and currently in Phase I for Head And Neck Cancer.

GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC ...

While tobacco and alcohol are known to increase the risk of head and neck cancer, new research has found the amount of coffee ...

In the latest statistical salvo of an ongoing debate, people who consumed more than four cups of caffeinated coffee daily had ...

Obsessed with chai Or Coffee Well its your day to be happy Recent research suggests that this daily ritual might be lowering ...

Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in first line recurrent/metastatic head ... this novel IO combination in head and neck squamous cell cancers with PD-L1 CPS <1.

The trial (NCT04225117) included 46 patients with recurrent or metastatic head and neck cancer who had previously received platinum-based therapy and a PD-(L)1 inhibitor. At baseline, the patients ...

While immunotherapies have transformed treatment of many types of cancer, they do sometimes fail to have an impact – as Merck & Co has just observed in a study of Keytruda in head and neck cancer.

The Jimmy Carter drug introduced the world to cancer immunotherapy, a treatment that differs from chemotherapy. Carter was ...